No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
BNTC Benitec Biopharma
- 6.9900
- +0.1700+2.49%
Close Apr 19 16:00 ET
- 7.0000
- +0.0100+0.14%
Post 19:03 ET
18.12MMarket Cap-684P/E (TTM)
7.0900High6.4260Low256.29KVolume6.8400Open6.8200Pre Close1.75MTurnover12.69%Turnover RatioLossP/E (Static)2.59MShares9.010052wk High1.17P/B14.12MFloat Cap1.860052wk Low--Dividend TTM2.02MShs Float3939.6222Historical High--Div YieldTTM9.74%Amplitude1.8600Historical Low6.8330Avg Price1Lot Size
Post-Market
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Benitec Biopharma's $40 Million Equity Financing Deal
12 Health Care Stocks Moving In Thursday's After-Market Session
GainersBio-Path Hldgs (NASDAQ:BPTH) stock moved upwards by 9.0% to $4.58 during Thursday's after-market session. The company's market cap stands at $3.4 million. Biora Therapeutics (NASDAQ:BIOR) share
Top Midday Gainers
AGBA Group (AGBA) agreed to merge with artificial intelligence-driven social video platform Triller. The financial-services company said the value of the proposed business combination would be $4 bill
Why Is Gene Therapy Developer Benitec Biopharma Stock Trading Higher On Thursday?
Thursday, Benitec Biopharma Inc (NASDAQ:BNTC) released interim clinical data from the 90-day timepoint following the administration of BB-301 to the study's first subject (Subject 1) treated in the BB
CGC, GENE and HOLO Among Mid-day Movers
Express News | Benitec Biopharma Shares Halted On Circuit Breaker To The Upside, Stock Now Up 29%
Comments
News
$Benitec Biopharma(BNTC.US$ Benitec Biopharma Inc: Bb-301 Has Been Granted Orphan Drug Designation by US FDA and EMA Committee for Orphan Medicinal Products (Comp)
3
$Benitec Biopharma(BNTC.US$ phase 1 :X
Update
$Benitec Biopharma(BNTC.US$ Benitec Biopharma Reports Positive Interim Clinical Trial Data for First Opmd Subject Treated With Bb-301 in Phase 1B/2a Study
$Benitec Biopharma(BNTC.US$
NEWS
Benitec Biopharma Reports Positive Interim Clinical Trial Data for First OPMD Subject Treated with BB-301 in Phase 1b/2a Study
Positive interim clinical trial data for the first OPMD subject treated with BB-301 in a Phase 1b/2a study
Improvements in swallowing function demonstrated in multiple measures following BB-301 administration
No serious adverse events reported, with transient GERD resolved with common medications
Encouraging early clinical trial result...
NEWS
Benitec Biopharma Reports Positive Interim Clinical Trial Data for First OPMD Subject Treated with BB-301 in Phase 1b/2a Study
Positive interim clinical trial data for the first OPMD subject treated with BB-301 in a Phase 1b/2a study
Improvements in swallowing function demonstrated in multiple measures following BB-301 administration
No serious adverse events reported, with transient GERD resolved with common medications
Encouraging early clinical trial result...
News
$Benitec Biopharma(BNTC.US$ Benitec Biopharma Announces Oversubscribed Private Placement Financing of $40.0 Million
4
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
